Armata Pharmaceuticals Announces Presentation of Topline Data from SWARM-P.a. Clinical Study at the North American Cystic Fibrosis Conference

Rhea-AI Summary

Armata Pharmaceuticals, Inc. will present topline data from their Phase 1b/2a SWARM-P.a. clinical trial at the North American Cystic Fibrosis Conference. The trial evaluates AP-PA02, an inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis. The presentation will take place on November 3rd during the Plenary II session.

LOS ANGELES, Oct. 30, 2023 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that topline data from the Company's Phase 1b/2a SWARM-P.a. clinical trial evaluating AP-PA02, a novel, inhaled multi-phage therapeutic for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis (CF) will be mentioned during the North American Cystic Fibrosis Conference (NACFC) Plenary II session. The conference is being held November 2-4, 2023, at the Phoenix Convention Center in Phoenix, AZ. Armata announced positive topline data from the SWARM-P.a. study in March 2023.

Plenary II presentation details:
Title:	"Micro-Management": The Changing Face of Infections in CF
Presenters:	Natalie E. West, MD, MHS, Johns Hopkins University Lucas R. Hoffman, MD, PhD, Pediatric Pulmonary, Seattle Children's Hospital
Date:	Friday, November 3rd
Time:	5:00pm – 6:15pm ET
Session:	Plenary Session II
Location:	North Ballroom A-D

For more information or to register: https://www.nacfconference.org/registration

About NACFC

NACFC provides a collaborative and educational forum for all CF professionals. The educational elements of the meeting program are targeted to physicians, nurses, research scientists, respiratory therapists, physical therapists, nutritionists, social workers, and pharmacists. This annual meeting brings together scientists, clinicians, and caregivers from around the world to discuss and share ideas on the latest advances in CF research, care, and drug development and to exchange ideas about ways to improve the health and quality of life for people with CF.

About Armata Pharmaceuticals, Inc.

Armata is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific cGMP manufacturing.

Media Contacts:

At Armata:
Pierre Kyme
Armata Pharmaceuticals, Inc.
ir@armatapharma.com
310-665-2928 x234

Investor Relations:
Joyce Allaire
LifeSci Advisors, LLC
jallaire@lifesciadvisors.com
212-915-2569

View original content to download multimedia:https://www.prnewswire.com/news-releases/armata-pharmaceuticals-announces-presentation-of-topline-data-from-swarm-pa-clinical-study-at-the-north-american-cystic-fibrosis-conference-301965126.html

SOURCE Armata Pharmaceuticals, Inc.

FAQ

What is the name of the company mentioned in the press release?

The company mentioned in the press release is Armata Pharmaceuticals, Inc.

What is the purpose of Armata Pharmaceuticals?

Armata Pharmaceuticals is a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections.

What is the name of the clinical trial mentioned in the press release?

The clinical trial mentioned in the press release is the Phase 1b/2a SWARM-P.a. trial.

What is AP-PA02?

AP-PA02 is a novel, inhaled multi-phage therapeutic being evaluated in the clinical trial for the treatment of chronic pulmonary Pseudomonas aeruginosa infections in people with cystic fibrosis.

When will the presentation of the topline data take place?

The presentation of the topline data will take place on Friday, November 3rd.

Where will the presentation be held?

The presentation will be held at the North American Cystic Fibrosis Conference at the Phoenix Convention Center in Phoenix, AZ.

How can I get more information or register for the conference?

For more information or to register for the conference, you can visit the following website: https://www.nacfconference.org/registration